瑞典与法国重大运动神经退行性疾病患病率上升的驱动因素(2003-2022)
该研究基于瑞典(2001-2016)和法国(2009-2022)两项全国性回顾性队列,分析帕金森病、多发性硬化和运动神经元病患病率上升的驱动因素。汇总模型显示三种疾病患病率均显著增加,但机制不同:多发性硬化患病率上升主要由生存改善驱动,运动神经元病反映发病率的真实增加,帕金森病患病率增长温和且 largely 独立于发病率。
要点
- 多发性硬化患病率上升主要由生存改善驱动,而非发病率增加。
- 运动神经元病患病率上升反映发病率的真实增加。
- 帕金森病患病率增长温和, largely 独立于发病率变化。
核心结论
- 多发性硬化患病率上升 largely 由生存驱动,运动神经元病患病率上升反映发病率真实增加,帕金森病患病率增长温和且 largely 独立于发病率。
研究设计与样本
- 两项全国性、基于人群的回顾性队列研究,分别纳入2001-2016年瑞典和2009-2022年法国所有居民,采用以国家为随机效应的混合效应回归模型分析趋势。
主要发现
- 2003至2022年汇总模型中,帕金森病患病率比每年为1.014(p<0.001),多发性硬化患病率比每年为1.029(p<0.001),运动神经元病患病率比每年为1.028(p<0.001)。
- 帕金森病粗发病率比每年为0.998(p<0.001),多发性硬化粗发病率比每年为0.992(p<0.001);帕金森病标化发病率比每年为0.986(p<0.001),多发性硬化标化发病率比每年为0.995(p<0.001)。
- 运动神经元病粗发病率比每年为1.018(p<0.001),标化发病率比每年为1.008(p<0.001)。
- 帕金森病诊断时预期寿命2003至2013年每年增加0.95个月(p<0.001),2013至2022年每年减少1.20个月(p=0.002)。
- 多发性硬化诊断时预期寿命整个研究期间每年增加2.35个月(p<0.001),运动神经元病每年增加0.34个月(p=0.01)。
临床怎么用
- 卫生保健规划需考虑不同疾病患病率上升的驱动机制差异:多发性硬化侧重生存管理,运动神经元病侧重病因与危险因素研究,帕金森病需关注非发病率因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The prevalence of Parkinson disease (PD), multiple sclerosis (MS), and motor neuron diseases (MNDs) is rising globally. However, it is unclear to what degree this is related to an increase in incidence or to improved survival after diagnosis. METHODS: We performed 2 nationwide, population-based, retrospective cohort studies, including all individuals living in Sweden between 2001 and 2016 and living in France between 2009 and 2022, respectively. Pooled mixed-effects regression models, with country as a random effect, were used to determine temporal trends in prevalence, crude and age-standardized and sex-standardized incidence, and age and life expectancy at diagnosis. RESULTS: Annualized prevalence of PD, MS, and MNDs increased significantly between 2003 and 2022 in the pooled model (PD: prevalence ratio [PR] per year = 1.014, p < 0.001; MS: PR = 1.029, p < 0.001; MND: PR = 1.028, p < 0.001). While the crude incidence of both PD and MS remained nearly stable over time (PD: incidence rate ratio [IRR] per year = 0.998, p < 0.001; MS: IRR = 0.992, p < 0.001), the standardized incidence showed a more marked decrease for PD (IRR = 0.986, p < 0.001) while remaining almost unchanged for MS (IRR = 0.995, p < 0.001). For MNDs, both the crude and standardized incidence increased over time (crude IRR = 1.018, p < 0.001; standardized IRR = 1.008, p < 0.001). Life expectancy at diagnosis of PD increased between 2003 and 2013 (+0.95 months per calendar year, p < 0.001) and then decreased between 2013 and 2022 (-1.20 months, p = 0.002), while it increased significantly over the entire study period for MS (+2.35 months, p < 0.001) and MNDs (+0.34 months, p = 0.01). DISCUSSION: These findings indicate that the rising MS prevalence is largely survival-driven and the rising MND prevalence reflects a true increase in incidence, whereas PD prevalence grows modestly, largely independent of incidence. Depending on the mechanism that drives prevalence, whether increased incidence reflecting changing risk factor exposures, improved survival due to therapeutic advances, or demographic aging of the population, inferences about underlying causes differ substantially between PD, MS, and MNDs, with direct implications for health care planning and etiologic research.
引用
- Guinebretiere O, Yang F, Wei D, et al. Drivers of Rising Prevalence in Major Motor Neurodegenerative Diseases: Temporal Trends in Sweden and France (2003-2022). Neurology. 2026. PMID: 42247653. doi:10.1212/WNL.0000000000218072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。